Date |
Place |
Time |
Speakers |
Title |
|
Lab |
18.09. |
SH 1-2,
P-floor |
11.00 |
Maija Bry |
The role of VEGF-B in the myocardium |
|
Alitalo |
|
| |
|
11.30 |
Eevi Kaasinen |
Gene Identification of Recessively Inherited Right Isomerism |
|
Aaltonen |
|
25.09. |
KOK 8-9,
P-floor |
11.00 |
Anna Kantola |
N-terminal variants of LTBP-4; transcriptional regulation and ECM targeting |
|
Keski-Oja |
|
| |
|
|
|
|
|
|
|
02.10. |
KOK 8-9,
P-floor |
11.00 |
Simonas Laurinavicius |
KSHV induces transdifferentiation of lymphatic endothelial cells in a 3-D endothelial cell model |
|
Ojala |
|
| |
|
11.30 |
Sirkku Karinen |
Systematic Search for candidate Genes in Cancers |
|
Hautaniemi |
|
09.10. |
KOK 8-9,
P-floor |
11.00 |
Olli Matilainen |
The proteasome and nucleolus |
|
Holmberg-Still |
|
| |
|
11:30 |
Johanna Partanen |
Epithelial organization as suppressor of c-Myc functions |
|
Klefström |
|
16.10. |
KOK 8-9,
P-floor |
11.00 |
Matteo Ugolini |
Manipulating different arms of the immune system to stimulate anti-tumor immunity: role of the Complement system |
|
Hemminki |
|
| |
|
11.30 |
Anastasiya Chernenko |
Identification of novel cancer associated molecules |
|
Laakkonen |
|
23.10. |
SH 1-2
,
P-floor |
11.00 |
Harri Sihto |
The primary tumor biological characteristics and the site of distant metastasis in breast cancer - the seed and soil hypothesis revisited |
|
Joensuu |
|
| |
|
11.30 |
Vilja Eskelinen |
Persecution of Myc-driven cancer cells by BH3 complexes and mimetics |
|
Klefström |
|
30.10. |
SH 1-2,
P-floor |
11.00 |
Taija af Hällström |
DNA damage responses in prostate epithelium |
|
Laiho |
|
| |
|
11.30 |
Anna-Kaisa Anttonen |
6q12-14 amplifications in squamous cell carcinoma of head and neck |
|
Monni |
|
06.11. |
SH 1-2
,
P-floor |
11.00 |
Karen Ahlnäs |
Bone marrow-derived pericyte-like cells |
|
Salven |
|
| |
|
11.30 |
Jimmy Wu |
Signal-response analysis of apoptosis pathway for multiple cancer cell lines |
|
Hautaniemi |
|
13.11. |
SH 1-2
,
P-floor |
11.00 |
Denis Tvogorov |
A VEGFR-3 blocking antibody defines a novel mechanism of receptor interaction and inhibitor design |
|
Alitalo |
|
| |
|
11.30 |
Taru Koski |
Role of genetic renal cell cancer risk modifiers in HLRCC |
|
Aaltonen |
|
20.11. |
SH 1-2 ,
P-floor |
11.00 |
Grzegorz Sarek |
KSHV lytic replication compromises apoptosis by p53 reactivation in primary effusion lymphomas |
|
Ojala |
|
| |
|
11.30
|
Arja Band
|
TGFß signaling and the Akt-pathway
|
|
Laiho
|
|
27.11. |
LS 3
,
P-floor |
11.00 |
Otto Hemminki |
Onkolytic adenovirus based on seretype 3 |
|
Hemminki |
|
| |
|
11.30 |
Jenni Tamminen |
Asbestos induced EMT-like events in lung epithelial cells |
|
Keski-Oja |
|
Information to the speakers:
Please plan your talk to last for 20 minutes, of which at least first 5 minutes should be reserved for introduction. We will have two talks per seminar. The Cancer Biology Progress Reports takes place in the P-floor seminar room 1-2 (or in lecture hall 2/3 in some occasions). You will get a notification of the location of each seminar on preceding Thursday by e-mail. Please bring your presentation on a CD, USB device, or in your own laptop.
Credits for students:
2 ECTS (15 attended seminars) + 0.8 ECTS from own presentation
Note! The seminars need not be attended during one year. In order to get the credits from your own presentation, you need to attend 15 seminars.
Contact persons for the fall period are
Pipsa Saharinen and Juha Klefström (firstname.surname@helsinki.fi, written without two dots above) |
